Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07540897 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial sites expanded: 17 → 20 locationsSecondary endpoints: details revised at 2 of 9 entries · Eligibility criteria expanded, about 5 wordsShow 2 more changesShow less
Secondary endpoints: details revised at 2 of 9 entries
Eligibility criteria expanded, about 5 words
MinorTrial sites expanded: 14 → 17 locationsStart date changed from estimate of Aug 2026 to Aug 13, 2026v8Show 1 more changeShow less
Start date changed from estimate of Aug 2026 to Aug 13, 2026
NotableStart date: Jun 2026 to Aug 2026Trial sites expanded: 10 → 14 locationsv7Show 1 more changeShow less
Trial sites expanded: 10 → 14 locations
MinorTrial sites expanded: 5 → 10 locationsv6
MinorRe-verified, no change to tracked fieldsv5
MinorTrial sites expanded: 1 → 5 locationsStart date: May 2026 to Jun 2026v4Show 1 more changeShow less
Start date: May 2026 to Jun 2026
MinorStudy Status, Referencesv3
NotableRecruitment openedStudy sites: 0 to 1v2Show 1 more changeShow less
Study sites: 0 to 1
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to measure decreases in daytime sleepiness, cataplexy (sudden loss of muscle tone), and disease symptoms in participants with NT1 when taking ALKS 2680 tablets compared with placebo tablets.